Evidence map›Paper›PMID 18991643›Full record

ReviewCurrent medicinal chemistry2008

Recent advances in artemisinin production through heterologous expression.

Patrick R Arsenault, Kristin K Wobbe, Pamela J Weathers

Abstract readReview
In one paragraph

Review in Current medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Assessment of Artemisinin Contents in SelectedMedicines (Basel, Switzerland) · 2019
    Article
  5. Biotechnological approaches for artemisinin production in Artemisia.World journal of microbiology & biotechnology · 2018
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Trichomes + roots + ROS = artemisinin: regulating artemisinin biosynthesis in Artemisia annua L.In vitro cellular & developmental biology. Plant : journal of the Tissue Culture Association · 2011
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patrick R ArsenaultWorcester Polytechnic Institute, Worcester, MA 01609, USA.
Kristin K Wobbe
Pamela J Weathers

Funding

Artemisinin Biosynthesis: Role of Reactive OxygenR15GM069562 · NIGMS · WORCESTER POLYTECHNIC INSTITUTE · PI WEATHERS, PAMELA J · 2004 to 2010
$692k
NIGMS NIH HHS 2R15 GM 069562-02NIGMS NIH HHS R15 GM069562
6 · The paper itself

Abstract

Artemisinin the sesquiterpene endoperoxide lactone extracted from the herb Artemisia annua, remains the basis for the current preferred treatment against the malaria parasite Plasmodium falciparum. In addition, artemisinin and its derivatives show additional anti-parasite, anti-cancer, and anti-viral properties. Widespread use of this valuable secondary metabolite has been hampered by low production in vivo and high cost of chemical synthesis in vitro. Novel production methods are required to accommodate the ever-growing need for this important drug. Past work has focused on increasing production through traditional breeding approaches, with limited success, and on engineering cultured plants for high production in bioreactors. New research is focusing on heterologous expression systems for this unique biochemical pathway. Recently discovered genes, including a cytochrome P450 and its associated reductase, have been shown to catalyze multiple steps in the biochemical pathway leading to artemisinin. This has the potential to make a semi-synthetic approach to production both possible and cost effective. Artemisinin precursor production in engineered Saccharomyces cerevisiae is about two orders of magnitude higher than from field-grown A. annua. Efforts to increase flux through engineered pathways are on-going in both E. coli and S. cerevisiae through combinations of engineering precursor pathways and downstream optimization of gene expression. This review will compare older approaches to overproduction of this important drug, and then focus on the results from the newer approaches using heterologous expression systems and how they might meet the demands for treating malaria and other diseases.

Indexed as

AntimalarialsArtemisia annuaArtemisininsBiosynthetic PathwaysEscherichia coliGenetic EngineeringMalariaPlants, Genetically ModifiedSaccharomyces cerevisiaeAntimalarialsartemisininArtemisinins

Identifiers

PMID18991643
PMCPMC2821817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.